Vorinostat Completed Phase 1 / 2 Trials for Hodgkins Disease (HD) / Malignant Lymphomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT00127140A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)
NCT00771472Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
NCT01421173Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
NCT01276717Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma